If Plaintiffs are correct, no party in this litigation adequately represents Lillys interest in seeing the appropriate application of section 503A for tirzepatide. The lawsuit is advancing in parallel to regulatory actions
The plaintiffs allege that they experienced severe digestive complications, including the necessity for gallbladder removal and the development of gastroparesis, due to using these drugs
In clinical trials, puerarin could also significantly decrease the urinary albumin excretion rate in patients with DKD (Wang et al., 2015a
Prior research demonstrated that PCB-DS mitigated MCAO by downregulating OS, which included reducing intracellular ROS and MDA levels (Zhou et al., 2023b)
Comparison with GLP-1GIP and semaglutide In DIO mice, GLP-1GIPLani dose-dependently decreased body mass, fat and lean tissue mass and food intake (Extended Data Fig